Results of Two Phase 3, Randomized, Placebo‐Controlled Trials
"The primary endpoint was stable response (platelets ≥50,000/μL at ≥4 of 6 biweekly visits, weeks 14‐24, without rescue therapy). Baseline median platelet count was 16,000/μL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P=0.0003). Overall responses (defined retrospectively as ≥1 platelet count ≥50,000/μL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P=0.0006). Median time to response was 15 days (on 100mg bid), and 83% responded within 8 weeks."
- From Wiley Online Library